Insiders of Corvus Pharmaceuticals Getting Good Value On Their US$1.03m Investment [Yahoo! Finance]
Corvus Pharmaceuticals, Inc. (CRVS)
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corvuspharma.com
Company Research
Source: Yahoo! Finance
NASDAQ:CRVS ) insiders, who had purchased shares in the previous 12 months were rewarded handsomely. The shares increased by 27% last week, resulting in a US$96m increase in the company's market worth, implying a 325% gain on their initial purchase. As a result, the stock they originally bought for US$1.03m is now worth US$4.39m. Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether. The Last 12 Months Of Insider Transactions At Corvus Pharmaceuticals The Co-Founder Richard Miller made the biggest insider purchase in the last 12 months. That single transaction was for US$1m worth of shares at a price of US$1.73 each. Even though the purchase was made at a significantly lower price than the recent price (US$7.35), we still think insider buying is a positive. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.
Show less
Read more
Impact Snapshot
Event Time:
CRVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVS alerts
High impacting Corvus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRVS
News
- Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewswire
- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
- Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisGlobeNewswire
- Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16% [Yahoo! Finance]Yahoo! Finance
CRVS
Earnings
- 11/12/24 - Miss
CRVS
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/13/25 - Form SCHEDULE
- 1/13/25 - Form 8-K
- CRVS's page on the SEC website